Physician Modified Endovascular Grafts (PMEG)
Primary Purpose
Abdominal Aortic Aneurysms
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Fenestrated Endovascular Graft
Sponsored by
About this trial
This is an interventional treatment trial for Abdominal Aortic Aneurysms focused on measuring AAA
Eligibility Criteria
Inclusion Criteria:
All patients must meet all of the following inclusion criteria to be eligible for enrollment into this study:
- Patient is > 18 years of age
- Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)
- Patient or Legally Authorized Representative has signed an Institutional Review Board (IRB) approved Informed Consent Form
- Patient is considered by the treating physician NOT to be a candidate for elective open surgical repair of the Juxtarenal AAA (i.e., category III or greater per American Society of Anesthesiology (ASA) classification; please refer to Appendix III: ASA Classification System). ASA category IV patients may be enrolled provided their life expectancy is greater than 1 year.
Patient has a juxtarenal abdominal aortic aneurysm that meets at least one of the following:
- Abdominal aortic aneurysm >5.5 cm in diameter
- Aneurysm has increased in size by 0.5 cm in last 6 months.
- Maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment
- Patient has patent iliac or femoral arteries that will allow endovascular access with the physician modified endovascular graft.
- Patient has a suitable non-aneurysmal proximal aortic neck length of > 2 mm inferior to the most distal renal artery ostium.
- Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of >15 mm. The resultant repair should preserve patency in at least one hypogastric artery.
- Patient has a suitable non-aneurysmal proximal aortic neck diameter between 20 and 32mm, averaged across the diameters at the Celiac, SMA, at the lowest patent renal artery and at the midpoint of the renal arteries.
- Patient has suitable non-aneurysmal distal common iliac diameters between 8 and 20 mm.
- Patient has juxtarenal aortic neck angulation < 60º
- Patient must be willing to comply with all required follow-up exam-
Exclusion Criteria:
Patients that meet ANY of the following are not eligible for enrollment into the study:
- Patient has a mycotic aneurysm or has an active systemic infection
- Patient has unstable angina (defined as angina with a progressive increase in symptoms,new onset at rest or nocturnal angina, or onset of prolonged angina)
- Patient has a major surgical or interventional procedure planned within +/- 30 days of the AAA repair.
- Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome).
- Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.
- Patient has a known allergy or intolerance stainless steel or gold
- Patient has a body habitus that would inhibit X-ray visualization of the aorta
- Patient has a limited life expectancy of less than 1 year
- Patient is currently participating in another investigational device or drug clinical trial
- Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.
Sites / Locations
- Harborview Medical CenterRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Fenestrated procedure
Arm Description
Fenestrated device with fenestrations for bilateral renal ateries and SMA. May include all three fenestrations or only one
Outcomes
Primary Outcome Measures
Safety and efficacy
The primary objectives of this study are to determine whether physician modified endovascular grafts are a safe and effective method of treating patients with elective, symptomatic or ruptured juxtarenal aortic aneurysms in those patients considered to be unsuitable candidates for open surgical repair and have no other options for treatment. The safety of physician modified endovascular grafts will be determined by evaluating the proportion of patients that experience a rate of Major Adverse Events. The Major Adverse Event rate will be compared to a performance goal.
Secondary Outcome Measures
Effectiveness
Technical Success, defined as successful delivery and deployment of the physician modified endovascular graft with preservation of those branch vessels intended to be preserved.
Freedom from Type I & III endoleaks
Freedom from stent graft migration
Freedom from AAA (Abdominal Aortic Aneurysm) enlargement
Full Information
NCT ID
NCT01538056
First Posted
February 18, 2012
Last Updated
May 19, 2022
Sponsor
University of Washington
1. Study Identification
Unique Protocol Identification Number
NCT01538056
Brief Title
Physician Modified Endovascular Grafts
Acronym
PMEG
Official Title
Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysm: An Investigator Initiated Study
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 2011 (undefined)
Primary Completion Date
January 2030 (Anticipated)
Study Completion Date
January 2035 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Washington
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The primary objectives of this study are to determine whether physician modified endovascular grafts are a safe and effective method of treating patients with elective, symptomatic or ruptured juxtarenal aortic aneurysms in those patients considered to be unsuitable candidates for open surgical repair and have no other options for treatment.
Detailed Description
15,000 Americans die suddenly each year from rupture of an aneurysm in the aorta,which is the ninth leading cause of death in men over age 55. Aortic aneurysms are four times more common in men than in women and usually occur in those over age 50. Approximately one percent of men between the ages of 55 and 64 will have a significant aneurysm, and the likelihood increases to about four to six percent of those men over the age of 75. In a recent population-based study of Medicare beneficiaries, 83.2% of patients undergoing endovascular repair of their aortic aneurysm were male. Furthermore, 11.9% of patients were 67 to 69 years of age, 26.8% 70 to 74, 35.7% 75 to 79, 15.8% 80 to 84 and 9.8% > 85 years of age. Ninety-six percent of patients were White, 3% Black and the rest either Hispanic or "Other". We have reason to believe that the current population of patients in the Pacific Northwest harboring abdominal aortic aneurysms match these statistics. Thus, women and minorities will definitely be under-represented in this study primarily due to the epidemiology of the disease process.
Our institution treats a large number of patients with aortic pathology including a large number of patients with symptomatic or ruptured abdominal aortic aneurysms. We recently published our results on the implementation of a protocol for managing these patients with endovascular techniques and have been able to reduce the mortality rate in half for the first time in over 30 years. Unfortunately, not all patients presenting with symptomatic or ruptured aortic aneurysms are candidates for endovascular repair. Reasons for exclusion predominantly involve lack of a suitable proximal aortic neck. Solutions to this problem involve multi-branched or "fenestrated" endografts which are being assessed in other clinical trials. However, grafts in these trials require between 6 and 12 weeks to manufacture and deliver to the investigational site.
On-site physician modification has also been described but is currently considered outside the Instructions For Use for the intended devices. Our institution's quality improvement department recently performed an objective review of 47 consecutive PMEG cases in patients presenting with asymptomatic, symptomatic or ruptured aortic aneurysms with highly encouraging results (See Many patients in our region do not have access to clinical trials involving emerging aortic endovascular therapies, and some have no other option due to urgent presentation or poor open surgical candidacy. For these important reasons, we seek to evaluate the safety and efficacy of PMEG using FDA-approved, off-the-shelf device in order to increase the applicability of these technologies to more patients and thus save more lives.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Abdominal Aortic Aneurysms
Keywords
AAA
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Fenestrated procedure
Arm Type
Experimental
Arm Description
Fenestrated device with fenestrations for bilateral renal ateries and SMA. May include all three fenestrations or only one
Intervention Type
Device
Intervention Name(s)
Fenestrated Endovascular Graft
Other Intervention Name(s)
FEVAR
Intervention Description
Modified endovascular graft with fenestrations to allow for blood flow to vital visceral vessels such as the renal arteries and SMA (Superior Mesenteric Artery).
Primary Outcome Measure Information:
Title
Safety and efficacy
Description
The primary objectives of this study are to determine whether physician modified endovascular grafts are a safe and effective method of treating patients with elective, symptomatic or ruptured juxtarenal aortic aneurysms in those patients considered to be unsuitable candidates for open surgical repair and have no other options for treatment. The safety of physician modified endovascular grafts will be determined by evaluating the proportion of patients that experience a rate of Major Adverse Events. The Major Adverse Event rate will be compared to a performance goal.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Effectiveness
Description
Technical Success, defined as successful delivery and deployment of the physician modified endovascular graft with preservation of those branch vessels intended to be preserved.
Freedom from Type I & III endoleaks
Freedom from stent graft migration
Freedom from AAA (Abdominal Aortic Aneurysm) enlargement
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All patients must meet all of the following inclusion criteria to be eligible for enrollment into this study:
Patient is > 18 years of age
Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)
Patient or Legally Authorized Representative has signed an Institutional Review Board (IRB) approved Informed Consent Form
Patient is considered by the treating physician NOT to be a candidate for elective open surgical repair of the Juxtarenal AAA (i.e., category III or greater per American Society of Anesthesiology (ASA) classification; please refer to Appendix III: ASA Classification System). ASA category IV patients may be enrolled provided their life expectancy is greater than 1 year.
Patient has a juxtarenal abdominal aortic aneurysm that meets at least one of the following:
Abdominal aortic aneurysm >5.5 cm in diameter
Aneurysm has increased in size by 0.5 cm in last 6 months.
Maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment
Patient has patent iliac or femoral arteries that will allow endovascular access with the physician modified endovascular graft.
Patient has a suitable non-aneurysmal proximal aortic neck length of > 2 mm inferior to the most distal renal artery ostium.
Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of >15 mm. The resultant repair should preserve patency in at least one hypogastric artery.
Patient has a suitable non-aneurysmal proximal aortic neck diameter between 20 and 32mm, averaged across the diameters at the Celiac, SMA, at the lowest patent renal artery and at the midpoint of the renal arteries.
Patient has suitable non-aneurysmal distal common iliac diameters between 8 and 20 mm.
Patient has juxtarenal aortic neck angulation < 60º
Patient must be willing to comply with all required follow-up exam-
Exclusion Criteria:
Patients that meet ANY of the following are not eligible for enrollment into the study:
Patient has a mycotic aneurysm or has an active systemic infection
Patient has unstable angina (defined as angina with a progressive increase in symptoms,new onset at rest or nocturnal angina, or onset of prolonged angina)
Patient has a major surgical or interventional procedure planned within +/- 30 days of the AAA repair.
Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome).
Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.
Patient has a known allergy or intolerance stainless steel or gold
Patient has a body habitus that would inhibit X-ray visualization of the aorta
Patient has a limited life expectancy of less than 1 year
Patient is currently participating in another investigational device or drug clinical trial
Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Benjamin W Starnes, MD
Organizational Affiliation
University of Washington
Official's Role
Principal Investigator
Facility Information:
Facility Name
Harborview Medical Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brenda R Kline, RN,ARNP
Phone
206-744-3369
Email
brenda99@uw.edu
First Name & Middle Initial & Last Name & Degree
Benjamin W Starnes, MD
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
33930518
Citation
Zettervall SL, Dansey K, Kline B, Singh N, Starnes BW. Significant aortic neck dilation occurs after repair of juxtarenal aneurysms with fenestrated endovascular aneurysm repair. J Vasc Surg. 2021 Oct;74(4):1090-1097.e2. doi: 10.1016/j.jvs.2021.03.060. Epub 2021 Apr 28.
Results Reference
derived
PubMed Identifier
33592291
Citation
Hemingway JF, Starnes BW, Kline BR, Singh N. Initial experience with the Terumo aortic Treo device for fenestrated endovascular aneurysm repair. J Vasc Surg. 2021 Sep;74(3):823-831.e1. doi: 10.1016/j.jvs.2021.01.042. Epub 2021 Feb 14.
Results Reference
derived
PubMed Identifier
31635961
Citation
Hurd JR, Chen X, Caps MT, Katsman D, Singh N, Zierler RE, Tatum B, Starnes BW. A reliable method for renal volume measurement and its application in fenestrated endovascular aneurysm repair. J Vasc Surg. 2020 May;71(5):1515-1520. doi: 10.1016/j.jvs.2019.07.089. Epub 2019 Oct 18.
Results Reference
derived
PubMed Identifier
23643560
Citation
Starnes BW, Tatum B. Early report from an investigator-initiated investigational device exemption clinical trial on physician-modified endovascular grafts. J Vasc Surg. 2013 Aug;58(2):311-7. doi: 10.1016/j.jvs.2013.01.029. Epub 2013 May 3.
Results Reference
derived
Learn more about this trial
Physician Modified Endovascular Grafts
We'll reach out to this number within 24 hrs